<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743912</url>
  </required_header>
  <id_info>
    <org_study_id>RFDI1008</org_study_id>
    <nct_id>NCT00743912</nct_id>
  </id_info>
  <brief_title>Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single Arm, Open-Label Study to Evaluate the Effect of Rifaximin 550 MG Tablets TID on the Pharmacokinetics of Orally Administered Midazolam in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine if rifaximin, administered daily has an
      effect on the cytochrome P450 (CYP) isoenzyme 3A4, by examining any changes in the
      pharmacokinetics of midazolam (a CYP3A4 substrate), when co-administered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-site, single-arm, open-label, drug-interaction study that examines the
      effect of rifaximin (RFX), 550 mg 3 times daily (TID; 1650 mg/day), on orally administered
      (PO) midazolam (MDZ) 2 mg (administered as a 2 mg dose in 1 mL of midazolam HCL Syrup; 2
      mg/mL) when dosed for 7 and 14 consecutive days, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual midazolam and rifaximin plasma concentrations and pharmacokinetic parameters will be summarized.</measure>
    <time_frame>21 to 38 days (including a 21 day screening period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall safety assessments will include the incidence, intensity, and type of adverse events, and clinically significant changes in the patient's physical examination, vital signs and laboratory results.</measure>
    <time_frame>21 tyo 38 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open-label rifaximin 550 mg TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifaximin</intervention_name>
    <description>550 mg TID</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is medically normal

          -  Patient has normal laboratory values

          -  Patient has the ability to understand the requirements of the study

        Exclusion Criteria:

          -  HIV

          -  Hepatitis B

          -  Hepatitis C

          -  History of renal, hepatic, endocrine, oncological, gastrointestinal or cardiovascular
             disease.

          -  History of epilepsy, asthma, diabetes, psychosis, glaucoma or severe head injury.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU, Inc</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <last_update_submitted>December 21, 2009</last_update_submitted>
  <last_update_submitted_qc>December 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Audrey Shaw, Director Clinical Development</name_title>
    <organization>Salix Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>rifaximin</keyword>
  <keyword>midazolam</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

